No Data
No Data
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
Express News | Prius: Shareholders' view is that Zhaotai plans to reduce its holdings by no more than 2%
Prius (301257.SZ): Actual controller Lai Chunbao completed an increase of 160,000 shares
Gelonghui, Feb. 7 | Prius (301257.SZ) announced that as of the announcement disclosure date, the company's chairman and actual controller Mr. Lai Chunbao's plan to increase his holdings had been completed. On February 7, 2024, Mr. Lai Chunbao increased his holdings of the company's shares by 160,000 shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.26% of the company's total share capital. The increase in holdings was 6,544,987 yuan (not including transaction fees). The increase amount of the above holdings increase entity has exceeded the lower limit of the amount of the plan to increase their holdings.
The actual controller of Prius (301257.SZ) plans to spend 5 million yuan to 8 million yuan to increase its holdings
Prius (301257.SZ) issued an announcement. Lai Chunbao, the actual controller of the company, plans to increase his holdings from the date of the announcement of this plan...
Prius (301257): Performance is expected to maintain high growth in line with expectations
Event: The company released its 2023 performance forecast. According to the company's forecast, the company expects a profit of 123-146 million yuan in 2023, an increase of 69.86%-101.63% over the same period last year, and is expected to deduct non-profit
Prius (301257.SZ): 2023 net profit pre-increased by 69.86% to 101.63%
Glonghui, January 22丨Prius (301257.SZ) announced its 2023 annual results forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 123.0 million yuan to 140.6 million yuan, an increase of 69.86% to 101.63% over the same period of the previous year; net profit profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10,400.00 million yuan to 124.0 million yuan, an increase of 55.41% to 85.30% over the same period last year. In 2023, the company closely revolves around the established development strategy, takes stability and progress as the general tone, and is active
No Data